Companies › Sensorion
1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SENS-501 Gene therapy for OTOF mutations | OTOF | Phase 1 | OTOF Gene Mutation | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06370351 | SENS-501 | Phase 1 | OTOF Gene Mutation | Other | Jul 2027 |
Eli Lilly Shanghai Euhearing Therapeutics Regeneron Pharmaceuticals
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.